FAYETTEVILLE, GA, UNITED STATES, March 10, 2026 /EINPresswire.com/ -- Spinal cord injury often triggers a cascade of ...

The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Comprehensive Enterprise Evidence-Based Patient Activation Intelligence Solution Connects Healthcare Value-Based Care Strategy to Measurable Results Across Access, Referral Closure, Care Transitions, ...

Growing evidence suggests the gut microbiome may influence how patients respond to GLP 1 obesity drugs. Researchers are ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Department of Civil and Environmental Engineering, The Hong Kong University of Science and Technology, Hong Kong, China Institute for Advanced Study, The Hong Kong University of Science and Technology ...

Sickle cell disease can lead to a severe complication known as acute chest syndrome (ACS), but the underlying mechanisms are not well understood. A new study by Mass General Brigham investigators ...